ISSN: 2329-9053

Journal of Molecular Pharmaceutics & Organic Process Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • J Mol Pharm Org Process Res 2016, Vol 4(1): 1
  • DOI: 10.4172/2329-9053.1000e125

HER2-Targeted Antibody Treatment for Ovarian Cancer Future Opportunities

Simon P Langdon1* and Andrew H Sims2
1Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom
2University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom
*Corresponding Author : Simon P Langdon, Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom, Tel: 0131 537 1763, Email: simon.langdon@ed.ac.uk

Received Date: Jun 21, 2016 / Accepted Date: Jun 23, 2016 / Published Date: Jun 27, 2016

Abstract

There are an estimated 240,000 new cases of ovarian cancer diagnosed worldwide each year. Due to late presentation, in many parts of the world it remains the most lethal gynecological cancer. In 2004, a new model description of this disease was proposed that combined both histopathological and molecular features and which classified epithelial ovarian cancers into two broad categories designated Type I and Type II tumors.

Keywords: Ovarian cancer; Chemotheraphy; Biomarkers

Citation: Langdon SP, Andrew H Sims (2016) HER2-Targeted Antibody Treatment for Ovarian Cancer – Future Opportunities. J Mol Pharm Org Process Res 4: e125. Doi: 10.4172/2329-9053.1000e125

Copyright: ©2016 Langdon SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 15772
  • [From(publication date): 6-2016 - Sep 19, 2024]
  • Breakdown by view type
  • HTML page views: 14748
  • PDF downloads: 1024
Top